- Differential uptake of herpes zoster vaccination associated with socioeconomic status: A population-based study in Stockholm County, Sweden. [Review]
- PDPharmacoepidemiol Drug Saf 2018 Sep 17
- CONCLUSIONS: Despite the vaccine being part of the National Pharmaceutical Benefit Scheme, receipt of the HZV was significantly associated with socioeconomic factors.
- Vaccines Hesitancy and the Dermatologist. [Journal Article]
- SSkinmed 2018; 16(4):219-221
- As primary care providers and experts on diseases affecting the skin, such as herpes zoster (shingles) and human papillomavirus-related cancers, dermatologists are often asked to make important recom...
As primary care providers and experts on diseases affecting the skin, such as herpes zoster (shingles) and human papillomavirus-related cancers, dermatologists are often asked to make important recommendations on vaccines and vaccinations; however, a rise in antivaccine attitudes-sometimes referred to as "vaccine hesitancy"-among patient populations, especially in North America and Europe, has created new challenges for the practicing dermatologist. Here we provide a brief overview of some of the major evidence that refutes commonly held misperceptions about vaccines.
- Assessing the effectiveness of zoster vaccine live: A retrospective cohort study using primary care data in the United Kingdom. [Journal Article]
- VVaccine 2018 Sep 05
- CONCLUSIONS: ZVL reduced the risk of shingles among an elderly population. Given the negative impact of shingles and PHN on QoL, the benefits of vaccination are clear. Improving uptake in the UK is needed in this population.
- Neurological and Ophthalmological Manifestations of Varicella Zoster Virus. [Journal Article]
- JNJ Neuroophthalmol 2018 Sep 01
- CONCLUSIONS: HZ produces a spectrum of potentially blinding and life-threatening complications that adversely affect quality of life and increase health care costs. Individuals at risk for HZ, such as the elderly and immunocompromised, should be encouraged to receive the highly effective VZV vaccine to prevent HZ and its complications.
- Vaccine-preventable disease following allogeneic haematopoietic stem cell transplant in Western Australia. [Journal Article]
- JPJ Paediatr Child Health 2018 Sep 05
- CONCLUSIONS: There is a high incidence of vaccine-preventable morbidity post-allogeneic HSCT in West Australian children. Viral aetiology constitutes the main burden, namely, influenza infection and varicella zoster virus reactivation. Further efforts are required to identify the most appropriate preventative strategies.
- Herpes Zoster and Herpes Zoster Vaccine Rates Among Adults Living with and without HIV in the Veterans Aging Cohort Study. [Journal Article]
- JAJ Acquir Immune Defic Syndr 2018 Aug 28
- CONCLUSIONS: Herpes zoster rates among PLWH have markedly decreased, but, even in cART-treated individuals, remain 50% higher than uninfected adults. Lower rates of zoster vaccine receipt combined with high rates of herpes zoster support the need for a safe and effective vaccine against herpes zoster for PLWH, formal zoster vaccine guidelines for PLWH, and consideration for expanded use at younger ages.
- Tale of two vaccines: differences in response to herpes zoster vaccines. [Journal Article]
- JCIJ Clin Invest 2018 Sep 04
- About one-third of the US population will develop herpes zoster (HZ, commonly known as shingles) over a lifetime, while two-thirds will not. It is not clear exactly why certain people are susceptible...
About one-third of the US population will develop herpes zoster (HZ, commonly known as shingles) over a lifetime, while two-thirds will not. It is not clear exactly why certain people are susceptible to HZ; however, we may be coming closer to an answer. In this issue of the JCI, a study by Levin et al. provides important details concerning pathogenesis of and protection from HZ. The authors characterized differences in the immunologic responses induced by two HZ vaccines, the live attenuated zoster vaccine (ZV) and the more recently developed adjuvanted varicella-zoster virus (VZV) glycoprotein E (gE) subunit herpes zoster vaccine (HZ/su), in vaccine-naive subjects and those previously vaccinated with HZ. The observed differences in responses paralleled the observed clinical protection of the two zoster vaccines, with HZ/su being superior to HZ. Together, these results seem to explain immunologically why the new subunit vaccine outperforms the live vaccine. These differences may also provide clues as to why HZ develops in the first place.
- Descriptive epidemiology of varicella based on national surveillance data before and after the introduction of routine varicella vaccination with two doses in Japan, 2000-2017. [Journal Article]
- VVaccine 2018 Sep 25; 36(40):5977-5982
- Routine childhood immunization using two doses of the varicella vaccine was introduced in Japan in October 2014. In this study, we analyzed the data extracted from national varicella surveillance, in...
Routine childhood immunization using two doses of the varicella vaccine was introduced in Japan in October 2014. In this study, we analyzed the data extracted from national varicella surveillance, including pediatric sentinel surveillance from 2000 to 2017 and hospitalized varicella surveillance from the 38th week of 2014 to the 37th week of 2017. Compared with the 2000-2011 baseline data, the number of varicella cases per sentinel decreased substantially by 76.6% overall and by 88.2% among children aged 1-4 years in 2017. Of 997 hospitalized patients, we found a decreasing trend in the number of cases among children aged <5 years. We also found a decreasing trend in the number of cases with complications among children aged 1-4 years. Data on the self-reported transmission sites in 35.5% (354/997) of the hospitalized varicella patients showed that transmission of varicella zoster virus (VZV) occurred frequently in household, at school for young children, in the workplace for adults, and at hospital for all age groups. Data from 29.0% (289/997) of the hospitalized patients with a self-reported source of infection showed that transmission of VZV occurred from a patient with herpes zoster (HZ) in 30.4% (88/289) of cases. Our data demonstrate a substantial decrease in the number of varicella cases in young children following introduction of routine childhood vaccination program with two-dose varicella vaccination in Japan. These data highlight the unique aspects of transmission sites across age groups and the important role of HZ cases in disease circulation.
- Persistence of varicella-zoster virus cell-mediated immunity after the administration of a second dose of live herpes zoster vaccine. [Journal Article]
- JIJ Infect Dis 2018 Aug 28
- Protection against zoster conferred by zoster vaccine live (ZVL; Zostavax™) wanes over time. We compared the cell-mediated immunity (VZV-CMI) of adults ≥70 years who received a second dose of ZVL ≥10...
Protection against zoster conferred by zoster vaccine live (ZVL; Zostavax™) wanes over time. We compared the cell-mediated immunity (VZV-CMI) of adults ≥70 years who received a second dose of ZVL ≥10 years after the initial dose with de novo-immunized age-matched controls. Before and during the first year after vaccination, VZV-CMI was significantly higher in re-immunized compared with the de novo vaccinees. At 3 years, VZV-CMI differences between groups decreased and only memory responses remained marginally higher in re-immunized participants. In conclusion, the increase in VZV-CMI generated by re-immunization with ZVL is at least equally persistent compared with de novo immunization.
New Search Next
- Infectious complications in the Southern Tasmanian kidney transplant population. [Journal Article]
- NNephrology (Carlton) 2018 Aug 27
- CONCLUSIONS: In conclusion, episodes of infection, hospitalization, antimicrobial use and development of multi-resistant organisms are common following kidney transplantation in this southern Tasmanian cohort. This study has identified several areas of focus for improved patient care including antimicrobial management of urinary tract infections, implementation of programmes to vaccinate KTx prior to transplantation, and development of transplantation specific antimicrobial stewardship programmes. This article is protected by copyright. All rights reserved.